Nurix Therapeutics, Inc., a leading clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and immune disorders, has announced the successful pricing of its upsized public offering. The company will issue 10,166,667 shares of its common stock at a price of $15.00 per share, raising a total of approximately $175.0 million in gross proceeds.
This significant capital raise will bolster Nurix’s financial position and support the advancement of its robust pipeline of small molecule therapies targeting various cancer and immune-related diseases. The proceeds from the offering will be used to fund ongoing clinical trials, preclinical studies, and research and development initiatives, as well as for general corporate purposes.
The upsized nature of the offering demonstrates the strong investor interest in Nurix’s innovative approach to drug discovery and development, which leverages its proprietary DELigase platform to create novel protein degraders and inhibitors. With this additional funding, Nurix is well-positioned to continue its mission of bringing transformative therapies to patients in need.